Progress in Myeloma - A Monoclonal Breakthrough.
Explore this paper's citation graph
Summary
In the past decade, overall survival among patients with myeloma has more than doubled, which is attributable in large part to the effective incorporation of lenalidomide and bortezomib into the modern therapy for the disease.
- Type
- letter
- Published
- 2016-10-05
- Cited by
- 35
- References
- 10
- OpenAlex
- https://openalex.org/W2528979204
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:45661089
Keywords
Medicine, Multiple myeloma, Lenalidomide, Bortezomib, Disease
References
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Cited by
- Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
- Daratumumab bei rezidiviertem oder refraktärem multiplem Myelom
- Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity
- Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma
- Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab
- How I treat first relapse of myeloma.
- How I treat myeloma with new agents.
- A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma
- Beyond Maximum Grade: Modernizing Adverse Event Assessment and Reporting in Haematologic Malignancies
- Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
- Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.
- Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries.
- Therapy for relapsed multiple myeloma.
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
- Multiple myeloma: Every year a new standard?
- Updates on CAR T‐cell therapy in B‐cell malignancies
Related papers
- Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
- [Proteasome inhibitors].
- The early marginal zone B cell initiated T independent type 2 response resists the proteasome inhibitor bortezomib
- Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
- Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma
- Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.
- Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma
- Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line
- Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
- Status of proteasome inhibitors in the treatment of multiple myeloma